Abstract :

This study evaluates the impact of the mini-competition method in pharmaceutical procurement in Indonesia, focusing on its challenges, risks, and regulatory implications. Mini-competition, a procurement method designed to promote competitive pricing in e-purchasing, has been introduced to streamline the procurement process, especially for essential goods such as pharmaceuticals. However, this method faces legal and practical challenges, including risks of fraud, reduced competition, collusion, and issues concerning product quality and innovation. The legal framework governing mini competition, including Presidential Regulation No. 12 of 2021, is analyzed to identify potential weaknesses in ensuring transparency and accountability.

The research also includes a case study of pharmaceutical product procurement, highlighting the significant price reductions resulting from mini competition but revealing adverse effects on industry sustainability. The analysis of the cost structure of pharmaceutical companies shows that continued price reductions may force companies to cease operations due to unprofitability. Drawing on international case studies, this study concludes that while mini competition can lower procurement costs, it also poses significant risks to product quality, innovation, and market competition. Traditional tender methods are proposed as a more balanced and sustainable approach for pharmaceutical procurement, emphasizing the need for transparent and comprehensive evaluation criteria.

---

Keywords :

Market Competition, Mini Competition, Pharmaceutical Procurement, Procurement Regulations, Transparency and Accountability.

---

References :

1. Sanchez-Graells, A. (2018). Competition and public procurement. European Journal of Public Procurement, 5(2), 99-115.
2. Albano, G. L., Spagnolo, G., & Zanza, M. (2009). Regulating joint bidding in public procurement. Journal of Public Procurement, 9(3), 245-268.
3. Vaidya, K., Sajeev, A. S. M., & Callender, G. (2006). Critical factors that influence e-procurement implementation success in the public sector. Journal of Public Procurement, 6(1-3), 70-99. https://doi.org/10.1108/JOPP-06-2006-0004
4. Zaenal Arifin dan Ade Haryani, “Analisis Pengadaan Barang dan Jasa”, Epigram, Vol. 11 No. 2, hlm. 118 (2014).
5. Peraturan Menteri Kesehatan Nomor 5 Tahun 2019 tentang Perencanaan dan Pengadaan Obat Berdasarkan Katalog Elektronik.
6. Bintang, P. P. (2024). The Potential Weakening of Open and Competitive Principles in Procurement Using the E-purchasing Method. Journal of Legal Communication, 10(1).
7. Keputusan Kepala LKPP Nomor 122 Tahun 2022 tentang Tata Cara Penyelanggaraan Katalog Elektronik
8. Simamora, Y. S., Kurniawan, F., Abrianto, B. O., & Amalia, R. (2021). Introduction to Procurement Law. Surabaya: Airlangga University Press.
9. Mantovani, R. (2023). Criminal Law Analysis of Unfair Business Competition in Tender Collusion Practices. Journal of Master of Legal Studies, 3(1), 53–71.
10. Peraturan Komisi Pengawas Persaingan Usaha Nomor 4 Tahun 2010 tentang Pedoman Pelaksanaan Ketentuan Pasal 11 tentang Kartel dalam Undang-Undang Nomor 5 Tahun 1999 tentang Larangan Praktek Monopoli dan Persaingan Usaha Tidak Sehat.
11. Rezmia, F. (2017). The Impact of Predatory Pricing Practices by Businesses from a Competition Law Perspective. Selat Journal, 4(2), 238.
12. Areeda, P., & Turner, D. (1975). Predatory pricing and related practices under section of the Sherman Act. Harvard Law Review, 88(4), 700-703.
13. Nicholson, W., & Snyder, C. (2017). Microeconomic Theory: Basic Principles and Extensions. Cengage Learning.
14. Corporate Finance Institute. (n.d.). Shutdown point. Corporate Finance Institute. Accessed on October 5, 2024, from https://corporatefinanceinstitute.com/resources/management/shutdown-point/
15. Schapper, P. R., Veiga Malta, J. N., & Gilbert, D. L. (2006). An analytical framework for the management and reform of public procurement. Journal of Public Procurement, 6(1-2), 1-26.
16. Rychłowska-Musiał, E. (2017). Real options games between two competitors: The case of price war. European Journal of Operational Research, 257(1), 124-136.
17. Liao, C.-H., Lu, N., Tang, C.-H., Chang, H.-C., & Huang, K.-C. (2018). Assessing the relationship between healthcare market competition and medical care quality under Taiwan’s National Health Insurance programme. Journal of Health Services Research & Policy, 23(1), 12-18.
18. Lábaj, M., Silanič, P., Weiss, C., & Yontcheva, B. (2017). Market structure and competition in the healthcare industry: Results from a transition economy. Health Economics Review, 7(1), 3.
19. Changalima, I. A., Ismail, I. J., & Mchopa, A. D. (2024). Effects of supplier selection and supplier monitoring on public procurement efficiency in Tanzania: A cost-reduction perspective. International Journal of Procurement Management, 15(1), 23-41.
20. Quesada, G., González, M. E., Mueller, J., & Mueller, R. (2010). Impact of e-procurement on procurement practices and performance. International Journal of Production Economics, 124(2), 256-268. https://doi.org/10.1016/j.ijpe.2009.11.009
21. Dash, P., & Meredith, D. (2010). When and how provider competition can improve health care delivery. Health Affairs, 29(3), 537-541.
22. Calipinar, H., & Soysal, M. (2012). E-procurement: A case study about the health sector in Turkey. Journal of Health Administration and Education, 29(4), 345-362.
23. Mavidis, A., & Folinas, D. (2022). From public e-procurement 3.0 to e-procurement 4.0: A critical literature review. Journal of Public Procurement, 22(2), 147-166.
24. Singh, P. K., & Chan, S. W. (2022). The impact of electronic procurement adoption on green procurement towards sustainable supply chain performance: Evidence from Malaysian ISO organizations. Journal of Cleaner Production, 251, 119415.
25. Nurchana, A. R. A., Haryono, B. S., & Adiono, R. (2012). The Effectiveness of E-Procurement in Goods/Services Procurement: A Study on the Implementation of E-Procurement in Goods/Services Procurement in Bojonegoro Regency. Journal of Economics and Development of Indonesia, 13(2), 142-156.
26. Dhiona Ayu Nani, & Syaiful Ali. (2018). Determinants of effective e-procurement system: Empirical evidence from Indonesian local governments. International Journal of Public Sector Management, 31(3), 231-247.
27. Deming, W. E. (1994). The new economics for industry, government, education (2nd ed.). Cambridge: M.I.T. Center for Advanced Engineering Study.
28. DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20-33.
29. Dunne, S., Shannon, B., Dunne, C., & Cullen, W. (2013). A review of the differences and similarities between generic drugs and their originator counterparts, including economic benefits associated with usage of generic medicines, using Ireland as a case study. BMC Pharmacology and Toxicology, 14(1), 1-19.
30. Pauwels, K., Huys, I., Casteels, M., & Simoens, S. (2014). Drug shortages in European countries: A trade-off between market attractiveness and cost containment? BMC Health Services Research, 14(1), 438.
31. Schweitzer, S. O., & Comanor, W. S. (2011). Controlling pharmaceutical prices and expenditures: The role of government regulation. Pharmacoeconomics, 29(1), 7-25.
32. Chaudhuri, S. (2014). The gap between successful innovation and access to its benefits: Indian pharmaceuticals. In The Globalization of Indian Business (pp. 135-154). Palgrave Macmillan, London.
33. Simoens, S., & De Coster, S. (2006). Sustaining generic medicines markets in Europe. Journal of Generic Medicines, 3(4), 257-268.
34. Feldman, R., & Frondorf, E. (2016). Drug wars: How big pharma raises prices and keeps generics off the market. Cambridge University Press.
35. Schneller, E. S. (2006). The value of group purchasing in the health care supply chain. Journal of Healthcare Management, 51(4), 235-244.
36. Ware, G., Moss, S., Campos, J. E., & Noone, G. P. (2007). Corruption in public procurement: A perennial challenge. In The many faces of corruption (pp. 295-334). World Bank.
37. McCrudden, C. (2007). Buying social justice: Equality, government procurement, and legal change. Oxford University Press.
38. Woodcock, J., & Woosley, R. (2008). The FDA critical path initiative and its influence on new drug development. Annual Review of Medicine, 59, 1-12.